Aktuellt
SENASTE
Redeye revisits its view on Isofol ahead of the make-or-break phase III AGENT top-line data for its only pipeline asset, arfolitixorin, in H1 2022. We maintain our positive view on the case and anticipate a successful trial readout. In anticipation of AGENT top-line data, we judge the share could rally to our new Base Case.
LÄS MER
